These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12611458)

  • 1. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines.
    Ellis CA; Vos MD; Wickline M; Riley C; Vallecorsa T; Telford WG; Zujewskil J; Clark GJ
    Breast Cancer Res Treat; 2003 Mar; 78(1):59-67. PubMed ID: 12611458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression.
    Doisneau-Sixou SF; Cestac P; Faye JC; Favre G; Sutherland RL
    Int J Cancer; 2003 Sep; 106(5):789-98. PubMed ID: 12866041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.
    Dalenc F; Giamarchi C; Petit M; Poirot M; Favre G; Faye JC
    Breast Cancer Res; 2005; 7(6):R1159-67. PubMed ID: 16457696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
    Moasser MM; Rosen N
    Breast Cancer Res Treat; 2002 May; 73(2):135-44. PubMed ID: 12088116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen.
    Abe-Hashimoto J; Kikuchi T; Matsumoto T; Nishii Y; Ogata E; Ikeda K
    Cancer Res; 1993 Jun; 53(11):2534-7. PubMed ID: 8495416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
    Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV
    Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer.
    Jordan VC; Gottardis MM; Robinson SP; Friedl A
    J Steroid Biochem; 1989; 34(1-6):169-76. PubMed ID: 2626014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
    Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
    BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen.
    Boyan BD; Sylvia VL; Frambach T; Lohmann CH; Dietl J; Dean DD; Schwartz Z
    Endocrinology; 2003 May; 144(5):1812-24. PubMed ID: 12697687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
    Mai Z; Blackburn GL; Zhou JR
    Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical data for Droloxifene.
    Hasmann M; Rattel B; Löser R
    Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
    Moasser MM; Sepp-Lorenzino L; Kohl NE; Oliff A; Balog A; Su DS; Danishefsky SJ; Rosen N
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1369-74. PubMed ID: 9465021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.